StocksMedium•25 September 2026•
1 min read
Precigen Shares Surge on B. Riley Buy Rating and FDA Platform Designation
Key Facts
1B. Riley initiated coverage on Precigen with a 'Buy' rating and a price target of $18.00.
2The U.S. FDA granted Precigen's AdenoVerse platform a platform technology designation to accelerate therapy development.
3The Papzimeos product generated $74.6 million in revenue during the first half of 2026.
B. Riley initiated coverage on Precigen with a 'Buy' rating and a price target of $18.00, according to Financial Modeling Prep. The U.S. FDA also granted the company's AdenoVerse platform a platform technology designation to accelerate the development of its gene and cell therapies.
PGEN closed at $7.70 on September 24, 2026, supported by its Papzimeos product which generated $74.6 million in revenue during the first half of 2026. The positive sentiment follows additional analyst momentum, including HC Wainwright increasing its price objective to $18.00.